More about our cookie policy.
HONG KONG – Tessa Therapeutics Pte, Singapore. Ltd.published the effects of two phase I/II trials initiated through researchers who revealed that their autologous CD30 CAR TT-11 mobile treatment showed a maximum rate of full long-lasting responses and a favorable protection profile in patients with relapsed/refractory Hodgkin lymphoma.
The studies, funded through Tessa, were conducted through researchers from Baylor College of Medicine and the Lineberger Comprehensive Cancer Center at the University of North Carolina (UNC).
The trials recruited 41 adult patients who gained the CD30 CAR T mobile remedy after chemotherapy lymphodepletion. The overall reaction rate in the 32 patients with active disease who gained fludarabine-based lymphydepletion was 72%, adding 19 patients (59%) with full answers.
Of those who participated in the studies, 94% were still alive one year after the remedy and 61% of those who had a full reaction also did not report recurrence symptoms a year later.
None of the patients had headaches that were observed in several trials with CD19 CAR T CELLS. The findings were published in the Journal of Clinical Oncology.
”These knowledge is vital because they demonstrate that cure with mobile CAR T can be a safe and effective remedy option for patients with Hodgkin lymphoma and potentially other lymphomas expressing CD30′,’ said Natalie Grover, co-author of the study and assistant professor in the DEPARTMENT of Medicine at UNC and a member of UNC Lineberger.
Extended to come
Ivan Horak, President of Studies and Development at Tessa, told BioWorld that the company plans to further explore the effects of a Phase II regulatory test through Tessa, which it plans to launch this year. “The TT-11 trial would be conducted at more than 22 sites in the United States and Europe,” he said.
The company’s clinical trial partners come with establishments in the United States such as MD Anderson, Baylor College of Medicine, Stanford Cancer Institute, City of Hope National Medical Center, UCSF Medical Center and Baylor Scott-White Health, as well as other centers in Massachusetts. Texas. And California.
The University of North Carolina granted Tessa an exclusive license to its patents, knowledge and experience, while Baylor College of Medicine granted Tessa the right to use her knowledge and experience to expand and commercialize therapy. Tessa declined to comment on monetary agreements due to confidentiality considerations.
Lately, Tessa’s portfolio has 4 IND-approved clinical trials, covering the evaluation of TT-11 in Hodgkin lymphoma, the company’s main program, which has a complex treatment designation in regenerative medicine, and non-Hodgkin lymphomas, as well as trials for TT-11X and TT-16. It also has a preclinical program for a candidate known as TT-20X, which will scan for express dual allogenic T cells of the CAR Epstein-Bar virus in counterfeit tumors. The company also plans TT-11 (HL) in paediatric patients, Horak said.
TT-16 is the subject of an upcoming Phase I trial initiated through researchers on counterfeit tumors positive for HER2. The FDA approved the start of the trial at Baylor College of Medicine.
Tessa is building a 90,000-square-foot internal GMP facility, which will be one of the company’s commercial-scale mobile treatment production facilities in Asia.
Enjoy a comprehensive policy for the ultimate holistic view of the market with BioWorld, BioWorld MedTech and BioWorld Asia in a single, easily accessible subscription.